Kwang Joo Park

Prof. Kwang Joo Park

Ajou University School of Medicine
+1
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Critical Care Medicine
Verified
Journal Article
Closed access
NANeill K. J. Adhikari
Neill K. J. Adhikari
RDR. Phillip Dellinger
R. Phillip Dellinger
SLStefan Lundin
Stefan Lundin
DPDidier Payen
Didier Payen
BVBenoit Vallet
Benoit Vallet
JFJan O. Friedrich
Jan O. Friedrich
Treatment with inhaled nitric oxide improves oxygenation but not survival in mechanically ventilated patients with acute respiratory distress syndrome, but the effect may depend on the severity of hypoxemia. Our objective was to determine whether nitric oxide reduces hospital mortality in patients with severe acute respiratory distress syndrome (PaO2/FIO2 ≤ 100 mm Hg) but not in patients with mild-moderate acute respiratory distress syndrome (100 < PaO2/FIO2 ≤ 300 mm Hg) at the time of randomization. Data were collected from Medline, Embase, and Cochrane CENTRAL electronic databases (inception to May 2013); proceedings from five conferences (to May 2013); and trial registries (http://www.clinicaltrials.gov and http://www.controlled-trials.com). No language restrictions were applied. Two authors independently selected parallel-group randomized controlled trials comparing nitric oxide with control (placebo or no gas) in mechanically ventilated adults or postneonatal children with acute respiratory distress syndrome. Two authors independently extracted data from included trials. Trial investigators provided subgroup data. Meta-analyses used within-trial subgroups and random-effects models. Nine trials (n = 1,142 patients) met inclusion criteria. Overall methodological quality was good. Nitric oxide did not reduce mortality in patients with severe acute respiratory distress syndrome (risk ratio, 1.01 [95% CI, 0.78–1.32]; p = 0.93; n = 329, six trials) or mild-moderate acute respiratory distress syndrome (risk ratio, 1.12 [95% CI, 0.89–1.42]; p = 0.33; n = 740, seven trials). Risk ratios were similar between subgroups (interaction p = 0.53). There was no between-trial heterogeneity in any analysis (I2 = 0%). Varying the PaO2/FIO2 threshold between 70 and 200 mm Hg, in increments of 10 mm Hg, did not identify any threshold at which the nitric oxide–treated patients had lower mortality relative to controls. Nitric oxide does not reduce mortality in adults or children with acute respiratory distress syndrome, regardless of the degree of hypoxemia. Given the lack of related ongoing or recently completed randomized trials, new data addressing the effectiveness of nitric oxide in patients with acute respiratory distress syndrome and severe hypoxemia will not be available for the foreseeable future.

1 July 2007 in Chest
Verified
Journal Article
Closed access
PDF file
JPJoo-hun Park
Joo-hun Park
KPKwang Joo Park
Kwang Joo Park
YKYoung Sun Kim
Young Sun Kim
SSSeung Soo Sheen
Seung Soo Sheen
KLKeu Sung Lee
Keu Sung Lee
SHSung Chul Hwang
Sung Chul Hwang

1 September 2009 in Lung Cancer
Verified
Journal Article
Closed access
HLHyun Woo Lee
Hyun Woo Lee
YCYong-Won Choi
Yong-Won Choi
JHJae Ho Han
Jae Ho Han
JKJang-Hee Kim
Jang-Hee Kim
JJJae Ho Jung
Jae Ho Jung
SSSeung Soo Sheen
Seung Soo Sheen

1 March 2008 in Respiratory Medicine
Verified
Journal Article
Closed access
KLKeu Sung Lee
Keu Sung Lee
YCYoung Hwa Choi
Young Hwa Choi
YKYoung Sun Kim
Young Sun Kim
SBSeung Hee Baik
Seung Hee Baik
YOYoon Jung Oh
Yoon Jung Oh
KPKwang Joo Park
Kwang Joo Park

1 January 2011 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
SLSeon-Heui Lee
Seon-Heui Lee
WCWon-Jung Choi
Won-Jung Choi
SSSook-Whan Sung
Sook-Whan Sung
YKYoung-Kyoon Kim
Young-Kyoon Kim
CKChi-Hong Kim
Chi-Hong Kim
KPKwang Joo Park
Kwang Joo Park
Lee SH, et al. Korean J Intern Med. 2011 Jun;26(2):137-144. http://dx.doi.org/10.3904/kjim.2011.26.2.137

1 April 2005 in Respiration
Verified
Journal Article
Closed access
KPKwang Joo Park
Kwang Joo Park
SHSung Chul Hwang
Sung Chul Hwang
SSSeung Soo Sheen
Seung Soo Sheen
YOYoon Jung Oh
Yoon Jung Oh
JHJae Ho Han
Jae Ho Han
KLKyi Beum Lee
Kyi Beum Lee
Background: Matrix metalloproteinase (MMP)-9 has been implicated in the development of pleural effusions. Objectives: The aim of this study was to assess the expression of MMP-9 in pleural effusions of tuberculosis, lung cancer and transudates. Methods: Ninety-one patients (37 tuberculous pleural effusions, 42 malignant pleural effusions of lung cancer and 12 transudates) were included. Concentrations of pleural fluid MMP-9 and tissue inhibitors of matrix metalloproteinase (TIMP)-1 were determined by immunoassay. We also investigated the cellular localization of MMP-9 and TIMP-1 by reverse-transcriptase polymerase chain reaction on lymphocytes from pleural effusions and by immunohistochemical analysis of pleural tissues. Results: Pleural fluid MMP-9 levels, MMP-9/total protein and MMP-9/TIMP-1 ratios were significantly higher in tuberculous pleural effusions, whilst TIMP-1 levels were similar in the three groups. MMP-9 levels positively correlated with TIMP-1 and lactate dehydrogenase levels, and negatively with pH and glucose levels in pleural effusions. MMP-9 mRNA expression in lymphocytes tended to be higher in malignant pleural effusions of lung cancer than in the other groups without reaching statistical significance. The strongest immunoreactivity for MMP-9 was observed in epithelioid cells of tuberculous pleural tissues. Much lower levels of MMP-9 expression were found in tumor cells of pleural tissues. Conclusions: MMP-9 is increased in tuberculous pleural effusions compared with transudates and malignant pleural effusions of lung cancer and is produced predominantly by epithelioid cells in the granulomas of tuberculous pleural tissues.